XML 64 R52.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue (Details)
$ in Thousands, ¥ in Billions
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2025
USD ($)
Mar. 31, 2025
JPY (¥)
Jan. 31, 2024
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Revenue recognized   $ 2,066 $ 22,121    
Deferred revenue, non-current   1,944 1,944    
ACELYRIN          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Development, regulatory and commercial milestone payments         $ 157,500
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Upfront, non-refundable payment $ 20,000        
Global development cost reimbursement 20,000        
Maximum achievement of regulatory milestones 36,000        
Maximum achievement of commercial milestones | ¥       ¥ 15.5  
Amount allocated to license obligation 17,400        
Amount allocated to Development Services Obligation 20,800        
Amount allocated to Material Right Obligation 3,300        
Deferred revenue, non-current   1,900 1,900    
Estimated amount of transaction price unsatisfied   19,400 19,400    
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Less than          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Collaboration revenue receivable   100 100    
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | License obligation          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Revenue recognized   0 17,400    
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Development services obligation          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Estimated amount of transaction price unsatisfied   16,200 16,200    
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Development services obligation and manufacturing services obligation          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Revenue recognized   2,100 4,700    
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Material right obligation          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Estimated amount of transaction price unsatisfied   $ 3,300 $ 3,300    
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Global development cost reimbursement in the dermatology field through the end of 2026          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Global development cost reimbursement 20,000        
Kaken | Collaborative Arrangement for Product envu, formerly known as ESK-001 | Estimated global development cost reimbursement in the dermatology field after 2026          
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]          
Global development cost reimbursement $ 1,500